Robert Buchanan

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Important steps in the development of cognitive-enhancing drugs in schizophrenia
    Robert W Buchanan
    Am J Psychiatry 163:1867-9. 2006
  2. doi request reprint William T. Carpenter jr: 35 years of clinical trials
    Robert W Buchanan
    To whom correspondence should be addressed Department of Psychiatry, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, US
    Schizophr Bull 40:S160-3. 2014
  3. doi request reprint Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia
    Robert W Buchanan
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
    J Clin Psychopharmacol 32:36-45. 2012
  4. ncbi request reprint Olanzapine treatment of residual positive and negative symptoms
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 162:124-9. 2005
  5. ncbi request reprint A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 31:5-19. 2005
  6. ncbi request reprint Morphometric assessment of the heteromodal association cortex in schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, Catonsville 21228, USA
    Am J Psychiatry 161:322-31. 2004
  7. pmc Persistent negative symptoms in schizophrenia: an overview
    Robert W Buchanan
    Department of Psychiatry, University of Maryland, School of Medicine, Maryland Psychiatry Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 33:1013-22. 2007
  8. pmc Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia
    Robert W Buchanan
    Schizophr Bull 33:1120-30. 2007
  9. ncbi request reprint Galantamine for the treatment of cognitive impairments in people with schizophrenia
    Robert W Buchanan
    Department of Psychiatry, University of Maryland, Baltimore, MD, USA
    Am J Psychiatry 165:82-9. 2008
  10. ncbi request reprint The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome
    Robert W Buchanan
    Maryland Psychiatric Research Center, Baltimore 21228, USA
    Schizophr Bull 28:63-73. 2002

Research Grants

  1. Advanced Centers for Interventions and Services Research
    Robert Buchanan; Fiscal Year: 2007
  2. Clozapine Treatment of Schizophrenic Patients
    Robert Buchanan; Fiscal Year: 2006
  3. CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS
    Robert Buchanan; Fiscal Year: 2000
  4. CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS
    Robert Buchanan; Fiscal Year: 1993

Detail Information

Publications69

  1. ncbi request reprint Important steps in the development of cognitive-enhancing drugs in schizophrenia
    Robert W Buchanan
    Am J Psychiatry 163:1867-9. 2006
  2. doi request reprint William T. Carpenter jr: 35 years of clinical trials
    Robert W Buchanan
    To whom correspondence should be addressed Department of Psychiatry, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, US
    Schizophr Bull 40:S160-3. 2014
    ....
  3. doi request reprint Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia
    Robert W Buchanan
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
    J Clin Psychopharmacol 32:36-45. 2012
    ..In conclusion, asenapine superiority over olanzapine was not observed in the core studies. Both treatments improved persistent negative symptoms, but discontinuation rates were higher with asenapine...
  4. ncbi request reprint Olanzapine treatment of residual positive and negative symptoms
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA
    Am J Psychiatry 162:124-9. 2005
    ..The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia...
  5. ncbi request reprint A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 31:5-19. 2005
    ....
  6. ncbi request reprint Morphometric assessment of the heteromodal association cortex in schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, Catonsville 21228, USA
    Am J Psychiatry 161:322-31. 2004
    ..To test this hypothesis, the authors measured prefrontal, inferior parietal, and superior temporal gyrus volumes and examined the pattern of connections among these regions...
  7. pmc Persistent negative symptoms in schizophrenia: an overview
    Robert W Buchanan
    Department of Psychiatry, University of Maryland, School of Medicine, Maryland Psychiatry Research Center, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 33:1013-22. 2007
    ....
  8. pmc Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia
    Robert W Buchanan
    Schizophr Bull 33:1120-30. 2007
    ..This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms...
  9. ncbi request reprint Galantamine for the treatment of cognitive impairments in people with schizophrenia
    Robert W Buchanan
    Department of Psychiatry, University of Maryland, Baltimore, MD, USA
    Am J Psychiatry 165:82-9. 2008
    ....
  10. ncbi request reprint The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome
    Robert W Buchanan
    Maryland Psychiatric Research Center, Baltimore 21228, USA
    Schizophr Bull 28:63-73. 2002
    ..Patients treated with conventional antipsychotic doses below the recommended dose range had significantly better role function. Prospective longitudinal studies are required to delineate the factors that may underlie this relationship...
  11. ncbi request reprint Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore, 21228, USA
    Am J Psychiatry 159:1035-43. 2002
    ....
  12. pmc The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 36:71-93. 2010
    ....
  13. pmc A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Maple and Locust Streets, Baltimore, MD 21228, USA
    Biol Psychiatry 69:442-9. 2011
    ..The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia...
  14. pmc The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
    Robert W Buchanan
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
    Schizophr Bull 37:1209-17. 2011
    ....
  15. pmc Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia
    David Potter
    University of Maryland School of Medicine, Department of Psychiatry, Baltimore, Maryland, USA
    Schizophr Bull 32:692-700. 2006
    ..These results suggest that considerably more work needs to be done to understand and validate the clinical significance of this impairment...
  16. ncbi request reprint Olanzapine effects on auditory sensory gating in schizophrenia
    Celso Arango
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    Am J Psychiatry 160:2066-8. 2003
    ..In the context of a double-blind comparison of olanzapine and haloperidol, the authors examined the effect of olanzapine on P50 suppression...
  17. ncbi request reprint The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes
    Celso Arango
    Maryland Psychiatric Research Center, Department of Psychariatry, University of Maryland, MD 21228, USA
    Am J Psychiatry 160:1421-7. 2003
    ..The study was designed to assess the predictive relationship between brain structure volume and positive and negative symptom response to clozapine and haloperidol...
  18. pmc Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
    Carol E Koro
    Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
    BMJ 325:243. 2002
    ..To quantify the association between olanzapine and diabetes...
  19. ncbi request reprint The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    Robert W Buchanan
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Am J Psychiatry 164:1593-602. 2007
    ..Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments...
  20. ncbi request reprint The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004
    ..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
  21. pmc Initial phase 2 trial of a nicotinic agonist in schizophrenia
    Robert Freedman
    Department of Psychiatry, Denver VA Medical Center and University of Colorado, Denver, CO 80262, USA
    Am J Psychiatry 165:1040-7. 2008
    ..The agent 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A) is a partial alpha(7)-nicotinic agonist and can be taken orally. A phase 1 trial showed evidence for cognitive enhancement in schizophrenia...
  22. ncbi request reprint No, it is not possible to be schizophrenic yet neuropsychologically normal
    Christopher M Wilk
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD 21228 0747, and Mental Illness Research, Education, and Clinical Center, Veterans Affairs Capital Health Care Network, USA
    Neuropsychology 19:778-86. 2005
    ..Thus, scoring in the normal range does not preclude neuropsychological abnormality in schizophrenia, confirming that neuropsychological impairment is a core feature of the illness...
  23. ncbi request reprint Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment
    Scott P Baymiller
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 59:49-57. 2003
    ..Concurrent beta-adrenergic receptor antagonist treatment may have an additive effect on serum lipids, and clozapine-associated weight gain also plays a modest role in triglyceride increases...
  24. doi request reprint The effects of galantamine on psychopathology in chronic stable schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 32:69-74. 2009
    ..This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia...
  25. pmc Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
    Cameron S Carter
    Department of Psychiatry, University of California, Davis, CA 95817, USA
    Biol Psychiatry 64:4-10. 2008
    ..The articles in this special section report on the results of the first conference, which used a criterion-based consensus-building process to develop a set of cognitive constructs to be targeted for translation efforts...
  26. ncbi request reprint Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia
    Christopher M Wilk
    Maryland Psychiatric Research Center, Sheppard Pratt Health System, Baltimore, 21228 0747, USA
    Am J Psychiatry 159:838-44. 2002
    ..This study examined the test-retest stability of the RBANS in individual patients with schizophrenia relative to a healthy comparison group...
  27. pmc Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date
    Alex S Cohen
    Department of Psychology, University of Maryland, College Park, USA
    Schizophr Bull 33:1201-12. 2007
    ..The question of whether deficit patients exhibit a unique cognitive impairment profile will require a more sophisticated and rigorous examination of the neuropsychology of the deficit syndrome...
  28. doi request reprint Lessons to take home from CATIE
    William T Carpenter
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Serv 59:523-5. 2008
    ..Bottom line: the dichotomy between first- and second-generation antipsychotics was not supported by efficacy data (and now, is not supported effectiveness data). Only clozapine has documented superiority in treatment-resistant cases...
  29. ncbi request reprint Working memory for visual features and conjunctions in schizophrenia
    James M Gold
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA
    J Abnorm Psychol 112:61-71. 2003
    ..Thus, the WM impairment in schizophrenia appears to be a consequence of attentional deficits rather than a reduction in storage capacity...
  30. doi request reprint Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia
    Celso Arango
    Departamento de Psiquiatria, Hospital General Universitario Gregorio Maranon, Unidad de Adolescentes, Dpto de Psiquiatría, C Ibiza 43, Madrid, Spain
    Psychiatry Res 162:91-100. 2008
    ....
  31. ncbi request reprint The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update
    Troy A Moore
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
    J Clin Psychiatry 68:1751-62. 2007
    ....
  32. ncbi request reprint Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans
    L Elliot Hong
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychophysiology 45:197-204. 2008
    ..The results suggested that beta oscillation indexed a neural process associated with the strength of sensory gating...
  33. ncbi request reprint Commentary on the Soteria project: misguided therapeutics
    William T Carpenter
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore 21228, USA
    Schizophr Bull 28:577-81; discussion 583-8. 2002
  34. pmc The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials
    Kristen J Prentice
    University of Maryland School of Medicine, Department of Psychiatry and Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 106:81-7. 2008
    ..In this study we tested the hypothesis that SZ patients, due to dysregulated error-processing mechanisms, are more fundamentally impaired in their on-line, trial-to-trial use of feedback to guide behavior...
  35. pmc Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine
    L Elliot Hong
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 35:632-40. 2010
    ..These electrical oscillatory indexes of subanesthetic ketamine can be potentially used to cross-examine glutamatergic pharmacological effects in translational animal and human studies...
  36. pmc Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 22147 Baltimore, MD 21228, United States
    Schizophr Res 103:161-8. 2008
    ..53, df=1, p=0.019), for an effect size of 0.4. These results suggest that galantamine has no effect on cigarette smoking and that during galantamine treatment nicotine dependency scores worsen...
  37. pmc Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate
    L Elliot Hong
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Arch Gen Psychiatry 65:1008-16. 2008
    ..Frequency-specific sensory gating may be less complex than the P50 response, and therefore closer to the direct genetic effects, and thus a more valid endophenotype...
  38. ncbi request reprint An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients
    Carol E Koro
    School of Pharmacy, University of Maryland, 506 W Fayette St, Suite 201, Baltimore, MD 21201, USA
    Arch Gen Psychiatry 59:1021-6. 2002
    ..Previous studies have suggested an association between olanzapine treatment and hyperlipidemia. We evaluated this association using a large health care database...
  39. pmc White matter alterations in deficit schizophrenia
    Laura M Rowland
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Neuropsychopharmacology 34:1514-22. 2009
    ..These findings provide further support for altered frontal-parietal network in deficit schizophrenia...
  40. ncbi request reprint A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 70:518-25. 2009
    ..In animals, it has been shown to increase extracellular levels of acetylcholine and dopamine in cortical and hippocampal regions...
  41. ncbi request reprint Summer birth and deficit schizophrenia: a pooled analysis from 6 countries
    Erick Messias
    Department of Psychiatry, School of Medicine, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Arch Gen Psychiatry 61:985-9. 2004
    ..In some reports, summer birth has been associated with deficit schizophrenia. Deficit schizophrenia and nondeficit schizophrenia also differ in several other ways...
  42. pmc The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009
    Julie Kreyenbuhl
    VA Capitol Health care Network VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore, MD, USA
    Schizophr Bull 36:94-103. 2010
    ..Another 13 psychopharmacologic and 4 psychosocial treatments had insufficient evidence to support a recommendation, representing significant unmet needs in important treatment domains...
  43. ncbi request reprint An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia
    Robert W Buchanan
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland at Baltimore, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 59:29-33. 2003
    ..These results suggest that cholinergic tone modulation may enhance selective behavioral functions in patients with schizophrenia, but further study is required to delineate the full extent of the potential benefit of this approach...
  44. ncbi request reprint Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia
    Susan dosReis
    Johns Hopkins Hospital, Division of Child and Adolescent Psychiatry, Baltimore, MD 21287 3325, USA
    Schizophr Bull 28:607-17. 2002
    ..Likewise, concurrent antiparkinsonian treatment exceeded the 1990 World Health Organization recommendations...
  45. ncbi request reprint Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval
    L Elliot Hong
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Am J Psychiatry 164:61-5. 2007
    ..The authors hypothesized that the relationship of the two measures may vary as a function of interstimulus intervals of stimulus presentations...
  46. ncbi request reprint Gamma/beta oscillation and sensory gating deficit in schizophrenia
    L Elliot Hong
    Maryland Psychiatric Research Center, Department of Psychiatry, School of Medicine, University of Maryland, PO Box 21247, Baltimore, MD 21228, USA
    Neuroreport 15:155-9. 2004
    ..The results of the present study showed that post-SI beta frequency response was inversely correlated to the S2 P50 response in patients with schizophrenia...
  47. ncbi request reprint The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003
    Anthony F Lehman
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Schizophr Bull 30:193-217. 2004
    ....
  48. ncbi request reprint Evidence-based treatment for schizophrenia
    Anthony F Lehman
    Department of Psychiatry University of Maryland School of Medicine, 701 West Pratt Street, Suite 388, Baltimore, MD 21201, USA
    Psychiatr Clin North Am 26:939-54. 2003
    ..Knowledge regarding how best to combine treatments to optimize outcomes is scarce...
  49. ncbi request reprint Weight and blood pressure change during clozapine treatment
    Scott P Baymiller
    Maryland Psychiatric Research Center Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Clin Neuropharmacol 25:202-6. 2002
    ..Although clozapine treatment is associated with weight gain, the correlation between this weight gain and increases in arterial blood pressure during the first year of treatment appears to be low...
  50. ncbi request reprint Visual perceptual and working memory impairments in schizophrenia
    Cenk Tek
    Maryland Psychiatric Research Center, PO Box 21246, Baltimore, MD 21228, USA
    Arch Gen Psychiatry 59:146-53. 2002
    ..In this study, we evaluated the integrity of the perceptual system for object and spatial visual information and the relevant working memory system, after adjusting for individual perceptual performance differences...
  51. ncbi request reprint The family pictures test as a measure of impaired feature binding in schizophrenia
    James M Gold
    Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA
    J Clin Exp Neuropsychol 26:511-20. 2004
    ..Such feature binding deficits likely implicate hippocampal dysfunction, consistent with neuroimaging evidence of structural and functional compromise of the medial temporal lobe in schizophrenia...
  52. ncbi request reprint Evoked gamma band synchronization and the liability for schizophrenia
    L Elliot Hong
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 70:293-302. 2004
    ....
  53. ncbi request reprint Racial disparity in the pharmacological management of schizophrenia
    Julie Kreyenbuhl
    Mental Illness Research, Education, and Clinical Center, VAMHCS Baltimore, MD 21201, USA
    Schizophr Bull 29:183-93. 2003
    ..A prospective, longitudinal evaluation is warranted to determine whether the observed patterns of prescribing are associated with poorer therapeutic outcomes in minority patients...
  54. ncbi request reprint Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia
    L Elliot Hong
    Department of Psychiatry, Maryland Psychiatric Research Center, School of Medicine, University of Maryland, Baltimore, 21228, USA
    Am J Med Genet B Neuropsychiatr Genet 136:8-11. 2005
    ..2%, P =0.050) forms of schizophrenia compared to controls (allele frequency 25.0%). We conclude that the DRP-2 *2236 C allele may mark another polymorphism in DRP-2, or in a nearby gene, that may influence susceptibility to schizophrenia...
  55. pmc Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychopharmacol 31:86-91. 2011
    ..The endocannabinoid system remains a promising target for pharmacotherapy of schizophrenia and obesity...
  56. doi request reprint Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine
    M Patricia Ball
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Catonsville, MD 21228, USA
    Clin Schizophr Relat Psychoses 5:17-25. 2011
    ..Therefore, we examined whether atomoxetine may be of benefit for those who have gained weight on either clozapine or olanzapine...
  57. ncbi request reprint Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status
    Christopher M Wilk
    Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228 0747, USA
    Schizophr Res 70:175-86. 2004
    ..Prior studies have established the clinical validity and test-retest reliability of the RBANS in SC...
  58. ncbi request reprint Prefrontal cortex, structural analysis: segmenting the prefrontal cortex
    Robert W Buchanan
    UT Southwestern Medical Center, Department of Psychiatry, 5323 Harry Hines Blvd, NC5 914, Dallas, TX 75390 9070, USA
    Am J Psychiatry 161:1978. 2004
  59. ncbi request reprint Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia
    Ikwunga Wonodi
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Am J Med Genet B Neuropsychiatr Genet 120:47-50. 2003
    ..These results provide support for a role of this variant in the etiopathophysiology of schizophrenia...
  60. ncbi request reprint Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 33:1217-28. 2008
    ..A significant and surprisingly large placebo/practice effect was observed among placebo-treated patients, and is a serious consideration in future clinical trial study designs for potential cognitive enhancing compounds in schizophrenia...
  61. ncbi request reprint Significance and meaning of neurological signs in schizophrenia: two decades later
    Igor Bombin
    Centro Estatal de Atencion al Daño Cerebral, Madrid, Spain
    Schizophr Bull 31:962-77. 2005
    ..These abnormalities have been argued to represent core features of the illness. We review studies published since our last review in 1988 that address the validity of neurological signs as a trait feature of schizophrenia...
  62. ncbi request reprint Prefrontal cortex and insight in schizophrenia: a volumetric MRI study
    Adegboyega Sapara
    King s College London, Institute of Psychiatry, Department of Psychology, London, UK
    Schizophr Res 89:22-34. 2007
    ..Future research should examine the association of specific dimensions of insight with frontal as well as non-frontal regional brain volumes...
  63. ncbi request reprint The Mount Sinai conference on the pharmacotherapy of schizophrenia
    Stephen R Marder
    VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
    Schizophr Bull 28:5-16. 2002
    ....
  64. ncbi request reprint Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  65. pmc Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia
    Hugh M D Gurling
    Molecular Psychiatry Laboratory, Department of Mental Health Sciences, University College London Medical School, Windeyer Institute of Medical Sciences, London, United Kingdom
    Arch Gen Psychiatry 63:844-54. 2006
    ..There is evidence of linkage to a schizophrenia susceptibility locus on chromosome 8p21-22 found by several family linkage studies...
  66. ncbi request reprint Galantamine-induced QTc prolongation
    Matthew W Nelson
    J Clin Psychiatry 67:166-7. 2006
  67. ncbi request reprint The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms
    Celso Arango
    Servicio de Psiquiatria, Hospital General Gregorio Maranon, C Ibiza 43, 280079 Madrid, Spain
    Eur Psychiatry 19:21-6. 2004
    ..The loss of precious human experiences and the association with poor long-term functional outcome justifies a focused and dedicated effort to discover the causes and treatments of this distinctive aspect of schizophrenia...
  68. ncbi request reprint Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia
    Nicole R Giuliani
    Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Whitehall Building, 200 Retreat Avenue, Hartford, CT 06106, USA
    Schizophr Res 74:135-47. 2005
    ..Although VBM is rapid and fully automated, it is not a replacement for manual ROI-based analyses. Both methods provide different types of information and should thus be used in tandem...
  69. ncbi request reprint Association between polymorphism of the SNAP29 gene promoter region and schizophrenia
    Ikwunga Wonodi
    Schizophr Res 78:339-41. 2005

Research Grants16

  1. Advanced Centers for Interventions and Services Research
    Robert Buchanan; Fiscal Year: 2007
    ....
  2. Clozapine Treatment of Schizophrenic Patients
    Robert Buchanan; Fiscal Year: 2006
    ..The study will provide new information on the clinical utility of adjunctive risperidone in treatment-resistant patients who fail to adequately respond to clozapine. ..
  3. CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS
    Robert Buchanan; Fiscal Year: 2000
    ..These data may provide new information about clozapine's mechanism of action and the pathophysiology of schizophrenia. ..
  4. CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS
    Robert Buchanan; Fiscal Year: 1993
    ..These data may provide new information about clozapine's mechanism of action and the pathophysiology of schizophrenia...